This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dealmaking in the life sciences sector comes with characteristics not typically seen in more traditional mergers and acquisitions (M&A). Deals often involve negotiating around complexities associated with both the unique nature of assets of life sciences companies and the unique industry ecosystem that brings these assets to life.
- Watch Here About the Guest(s): Nicholas Hulewsky is a seasoned entrepreneur and investor with a rich background in healthcare and mergers and acquisitions. The conversation touches on topics like market research, off-market acquisitions, building relationships, and identifying opportunities with great potential.
E247: Why Accurate Financials are Key to Success in Buying, Selling, and Valuing Businesses - Watch Here About the Guest(s): Ryan Hutchins is an accomplished entrepreneur and expert in the field of mergers and acquisitions. In the fast-paced world of mergers and acquisitions, the role of business valuation cannot be underestimated.
International mergers and acquisitions (M&A) offer the potential for rapid market expansion, access to cutting-edge technologies, and significant cost savings. Knowing whether to approach a single decision-maker or engage with a group can be essential for successful negotiations.
One of these “new” strategies that has grown in popularity over the past decade is the concept of “roll-ups” (also sometimes called “platform acquisition strategies”). This begs an important question: why do roll-ups receive a higher value than smaller acquisition targets? and thus receive volume discounts with better pricing.
September 2024), the Delaware Chancery Courts found buyers liable for failure to comply with negotiated earnout covenants – and in the latter case, awarded the plaintiffs more than $1 billion in damages. In this post, we recap the unique facts of each case, the negotiated efforts covenant and key takeaways. Johnson & Johnson (Del.
Are you a business leader eyeing expansion through acquisitions or an investor weighing potential mergers? Delve into fundamental concepts like EBITDA multiples, discount rates, and terminal values, empowering you to wield sound judgment in the realm of mergers and acquisitions.
No longer just “acquihires,” today’s innovation-driven acquisition is focused on talent retention. One familiar technique used by sophisticated tech buyers is a holdback structure that subjects a portion of key employees’ merger consideration to revesting. The typical revesting period for these arrangements is 24 to 36 months.
according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. Similarly, PE-backed platform companies have undergone substantial consolidation through mergers and acquisitions.” Tahoe still owns a minority interest. US Oncology Network.
Nonsan, South Korea-based Routejade makes graphite-based lithium-ion batteries for consumer electronics such as wearable technology, as well as in medical, industrial military applications. production capacity after it went public through a special purpose acquisition company. So, it’s a lot of intellectual property.
Ron Concept 1: Know The Risks of M&A When it comes to mergers and acquisitions (M&A), it is essential to understand the risks involved. Additionally, an attorney can help to negotiate and draft the necessary documents to ensure that the deal is legally sound. Subscribe to The Hub - Acquisitions Hub
For example, while a pharmaceutical company focused solely on shareholder value might prioritize high-margin drugs for rare conditions, a stakeholder-oriented approach might consider affordability and broader societal health needs , as seen with Gilead's approach to its HIV medications.
Thoroughly reviewing and verifying financial statements is essential to avoid unexpected setbacks and ensure your acquisition is based on a solid financial foundation. A clear illustration of this is in the healthcare industry, where compliance with HIPAA and medical licensing regulations is non-negotiable.
But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.
Federal Trade Commission (FTC) are particularly focused on acquisitions of “nascent technologies” by incumbent high-tech platforms. Scrutiny has become increasingly intense if the primary benefit of the deal appears to stultify a budding competitive threat – the so-called “killer acquisition.”
1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.
billion tie-up between Inmarsat and Viasat was cleared by both regulators, Adobe’s $20 billion proposed acquisition of Figma was abandoned in December 2023 following regulatory pressure. For example, while the $7.3
The year started off with a bang, with mega-deals such as Microsoft’s pending $69 billion acquisition of Activision Blizzard, Elon Musk’s $44 billion acquisition of Twitter and Broadcom’s pending $61 billion acquisition of VMware inked in quick succession. Tech M&A in 2022 was a tale of two halves.
An M&A advisor is a specialized professional who guides businesses through the intricate mergers and acquisitions process. This data-driven approach provides a comprehensive valuation, ensuring realistic expectations and a stronger position during negotiations with buyers. What Is an M&A Advisor?
billion acquisition of Alpine Immune; by contrast, there were eight US biotech acquisitions exceeding $5 billion in 2023. 2024 saw companies focusing on internal research and development, innovative partnerships, and targeted bolt-on asset acquisitions to bolster their pipelines. from 2023. [1]
But customer acquisition costs via Google and Facebook ad campaigns have risen over time and eaten into margins, so building a brand is still difficult. To give a deal example, well look at Sycamores ~$24 billion acquisition of Walgreens , which had been a public company for almost 100 years.
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content